We studied the characterization of
cabergoline, a new ergot
alkaloid derivative and a selective
dopamine D2 receptor agonist, in comparison to
bromocriptine and
pergolide in
reserpine-treated rodents.
Cabergoline (0.25-1.0 mg/kg, s.c.) improved dose-dependently the
reserpine-induced akinesia that was assessed on the locomotor activity, and the efficacy lasted longer than those of
bromocriptine (1.25-5.0 mg/kg, s.c.) or
pergolide (0.0625-0.5 mg/kg s.c.).
Cabergoline (ED50 = 1.10 mg/kg, at 4 h after the administration of drugs) also reversed
catalepsy, the failure to correct an externally imposed posture, and its efficacy was stronger and longer than
bromocriptine (ED50 = 4.65 mg/kg, at 4 h). Further,
reserpine-induced rigidity was improved equally by
cabergoline (0.125-1.0 mg/kg, i.v) and
bromocriptine (1.0 mg/kg, i.v.). When
cabergoline was administered together with 3(3,4-dihydroxyphenyl)-L-alanine (
L-DOPA), the effects were additive. Our results indicate that the long-lasting effects of
cabergoline could be beneficial for treating
Parkinson's disease.